HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

David Wallace

Executive Editor

Birmingham, UK

Having previously worked in the European chemicals industry, Dave has been with Generics Bulletin since 2010. Keeping a close eye on deals, corporate strategy and market developments in the off-patent sector, he also brings his background and education in law to bear on industry litigation as well as national legislative and regulatory affairs, with a particular interest in France where he has lived and studied in the past. A regular delegate to generics and biosimilars events and conferences as well as a frequent panel moderator, he maintains close links with industry representatives around the world. He also organizes and judges the annual Global Generics & Biosimilars Awards. In his spare time, he enjoys art and playing the piano.

Latest From David Wallace

Samsung Bioepis And Sandoz Get EU Nod For Stelara Rival

Samsung Bioepis has received an EMA nod for its Sandoz-partnered Stelara biosimilar under the name Pyzchiva. Meanwhile, the agency’s CHMP also recommended granting centralized marketing authorizations for two Accord generics.

Biosimilars Generic Drugs

Teva Commits To Dual Branded And Generic Model

Teva’s innovative and generic interests can not only co-exist but are complementary, CEO Richard Francis has set out, in response to questions over whether the Israeli giant would consider splitting its businesses to focus more on branded drugs.

Strategy Generic Drugs

French Proposals On Supply-Chain Security ‘Could Aggravate The Situation’

Proposed French legislation that would address shortages by strengthening obligations to hold security stocks – with the threat of sanctions for suppliers – would be counter-productive, local generics industry association Gemme has warned.

France Legislation

Azithromycin Leads Off UK Rises In January

Azithromycin topped our rundown of the steepest UK generic trade price rises in January 2024, based on figures from WaveData.

Market Intelligence Generic Drugs

Philippines FDA Slashes Approval Timelines For Generic Drugs

The Philippines Food and Drug Administration is set to shorten the timeline for generic review and approval from 120 days to just 45 days, as part of efforts to register new generics and bring down prices.

Regulation Policy

Philippines FDA Slashes Generic Approval Timelines

The Philippines Food and Drug Administration is set to shorten the timeline for generic review and approval from 120 days to just 45 days, as part of efforts to register new generics and bring down prices.

Regulation Policy
See All
UsernamePublicRestriction

Register